Icotinib Combined With WBRT For NSCLC Patients With Brain Metastases and EGFR Mutation

Phase 1/2 Completed 15 enrolled Betta Pharmaceuticals Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and tolerability of Icotinib at different dose levels in combination with whole brain radiotherapy for NSCLC patients with brain metastases and EGFR mutation.

Timeline

Start: 2011-12
Primary completion: 2013-06
Completion: 2013-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Icotinib	Small molecule	125 mg	—
Subject	Icotinib	Small molecule	250 mg	—
Subject	Icotinib	Small molecule	375 mg	—
Subject	Icotinib	Small molecule	500 mg	—

Icotinib Combined With WBRT For NSCLC Patients With Brain Metastases and EGFR Mutation

Summary

Timeline

Drugs

Indications